← Human Trials & Peer-Reviewed Studies
Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5
Plain-language guide to PMID 25362221 (2014): placebo-controlled randomized controlled trial study of Parathyroid Hormone (PTH 1-84) in 8 women.
Key Facts
- PMID
- 25362221
- Journal
- Iranian journal of kidney diseases
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Haghverdi F et al. (5 authors)
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.
This study was aimed to investigate the effects of raloxifene on intact parathyroid hormone (PTH) level and bone mineral density (BMD) for 8 months in women on hemodialysis and women with chronic kidney disease stage 5 not dependent on dialysis to determine its effect on secondary hyperparathyroidism and osteoporosis.
Who Took Part
The abstract describes 8 women taking part.
The age groups tagged for this paper are middle-aged adults, women only.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.
A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.
The methods mention a period of 8 months.
Baseline blood determinations and BMD were done and repeated after 8 months.
Serum levels of total calcium, phosphorus, alkaline phosphatase, and intact PTH were measured.
What Was Measured
The subject headings attached to it are Alkaline Phosphatase, Bone Density, Bone Density Conservation Agents, Bone Diseases, Metabolic, Calcium, Hyperparathyroidism, Secondary and Osteoporosis, Postmenopausal.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 8 women over 8 months.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2014 (Iranian journal of kidney diseases), a journal based in Iran.
More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.